These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 23037652)

  • 1. Hyperammonemia associated with valproic acid use in elderly psychiatric patients.
    Holroyd S; Overdyke JT
    J Neuropsychiatry Clin Neurosci; 2012; 24(3):372-4. PubMed ID: 23037652
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of valproate-induced hyperammonemia.
    Stewart JT
    J Am Geriatr Soc; 2005 Jun; 53(6):1080. PubMed ID: 15935047
    [No Abstract]   [Full Text] [Related]  

  • 3. Valproate-associated hyperammonemic encephalopathy.
    Wadzinski J; Franks R; Roane D; Bayard M
    J Am Board Fam Med; 2007; 20(5):499-502. PubMed ID: 17823470
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Valproic acid-induced hyperammonemia and minimal hepatic encephalopathy prevalence among psychiatric inpatients.
    Thomas KL; La AQ; Punia S; Doroudgar S; Perry PJ
    Ann Clin Psychiatry; 2016 Feb; 28(1):37-42. PubMed ID: 26855984
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ammonia induced encephalopathy from valproic acid in a bipolar patient: case report.
    Elgudin L; Hall Y; Schubert D
    Int J Psychiatry Med; 2003; 33(1):91-6. PubMed ID: 12906346
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reversible Encephalopathy due to Valproic Acid Induced Hyperammonemia in a Patient with Bipolar I Disorder: A Cautionary Report.
    Patel N; Landry KB; Fargason RE; Birur B
    Psychopharmacol Bull; 2017 Jan; 47(1):40-44. PubMed ID: 28138203
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Valproate-induced hyperammonemia in mental retardation: a case report and review of the literature.
    Khoo CL; Naik S; Lua R; Chai SB; Liew A; Sim K
    Prog Neuropsychopharmacol Biol Psychiatry; 2010 Apr; 34(3):561-2. PubMed ID: 20184937
    [No Abstract]   [Full Text] [Related]  

  • 8. Valproate-Induced Hyperammonemic Encephalopathy in General Hospital Patients With One or More Psychiatric Disorders.
    Lewis C; Tesar GE; Dale R
    Psychosomatics; 2017; 58(4):415-420. PubMed ID: 28411969
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Valproate-induced hyperammonemic encephalopathy. Review of cases in the psychiatric setting].
    Fassi G; Igoa A; Liste OA
    Vertex; 2008; 19(82):371-7. PubMed ID: 19424520
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical alertness to valproic acid-induced hyperammonemia--two case reports.
    Shan JC; Hsieh MH; Liu CC; Wen CC; Liu CM
    J Psychopharmacol; 2010 Jun; 24(6):943-5. PubMed ID: 19304858
    [No Abstract]   [Full Text] [Related]  

  • 11. Hyperammonemia following intravenous valproate loading.
    DeWolfe JL; Knowlton RC; Beasley MT; Cofield S; Faught E; Limdi NA
    Epilepsy Res; 2009 Jul; 85(1):65-71. PubMed ID: 19299111
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Valproic acid-associated hyperammonemic encephalopathy: a case report from the psychiatric setting.
    Kimmel RJ; Irwin SA; Meyer JM
    Int Clin Psychopharmacol; 2005 Jan; 20(1):57-8. PubMed ID: 15602119
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Valproic acid-induced hyperammonemia and thrombocytopenia in an elderly woman.
    Mallet L; Babin S; Morais JA
    Ann Pharmacother; 2004 Oct; 38(10):1643-7. PubMed ID: 15316109
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aripiprazole-related hyponatremia and consequent valproic acid-related hyperammonemia in one patient.
    Lin MW; Chang C; Yeh CB; Tai YM; Chang HA; Kao YC; Tzeng NS
    Aust N Z J Psychiatry; 2017 Mar; 51(3):296-297. PubMed ID: 27694641
    [No Abstract]   [Full Text] [Related]  

  • 15. Valproate-induced hyperammonaemia.
    Raja M; Azzoni A
    J Clin Psychopharmacol; 2002 Dec; 22(6):631-3. PubMed ID: 12454569
    [No Abstract]   [Full Text] [Related]  

  • 16. Risk factors for hyperammonemia associated with valproic acid therapy in adult epilepsy patients.
    Yamamoto Y; Takahashi Y; Suzuki E; Mishima N; Inoue K; Itoh K; Kagawa Y; Inoue Y
    Epilepsy Res; 2012 Sep; 101(3):202-9. PubMed ID: 22542569
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Valproate-induced hyperammonemic encephalopathy associated with urinary tract infection and urinary retention in the psychiatric setting.
    Dawson LP; Lee SJ; Hollander YS
    Aust N Z J Psychiatry; 2016 Nov; 50(11):1110. PubMed ID: 27056174
    [No Abstract]   [Full Text] [Related]  

  • 18. Influence of glutamine synthetase gene polymorphisms on the development of hyperammonemia during valproic acid-based therapy.
    Inoue K; Takahashi T; Yamamoto Y; Suzuki E; Takahashi Y; Imai K; Inoue Y; Hirai K; Tsuji D; Itoh K
    Seizure; 2015 Dec; 33():76-80. PubMed ID: 26599579
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Valproate-related hyperammonemic encephalopathy: report of 1 case.
    Selvi Y; Annagur BB; Sayin AA; Akbaba N
    J Clin Psychopharmacol; 2014 Jun; 34(3):e1. PubMed ID: 24633004
    [No Abstract]   [Full Text] [Related]  

  • 20. Ammonemia in bipolar patients on maintenance treatment with valproic acid.
    Bocchetta A; Siddu A; Sardu C; Sarnicola A; Martinelli V
    J Clin Psychopharmacol; 2012 Feb; 32(1):148-50. PubMed ID: 22217957
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.